Approximately when was Platinib officially launched?

Pralsetinib is a targeted drug specifically used to treat cancer patients carrying RET gene fusion mutations. It was developed by the American company Blueprint Medicines. This drug obtained approval from the U.S. Food and Drug Administration (FDA2020 >), the initial indication is to treat patients with RET fusion-positive advanced non-small cell lung cancer (NSCLC). As one of the first tyrosine kinase inhibitors targeting RET fusion mutations, the launch of platinib has filled the gap in the long-term lack of precise treatment drugs for patients with this type of lung cancer.

Platinib's approval was based on a multicenter, open-label clinical trial calledARROW. Data show that platinib has demonstrated good therapeutic effects in both untreated and previously treated patients with RET fusionNSCLC. Especially among patients who have received chemotherapy, the objective response rate (ORR) exceeds 60%, and most patients have longer response times and better treatment tolerance. These data demonstrate that platinib not only has a rapid onset of action but also has the potential to achieve long-term disease control.

With the increasing global emphasis on targeted therapy, platinib was also approved by the China National Medical Products Administration (NMPA) in 2021, becoming one of the first RET targeted drugs to be launched in China. However, although the drug has been approved for marketing in China, it is still not included in the national medical insurance directory, which means that patients need to purchase it at their own expense. According to market information, the price of platinib's original drug is relatively high. Common specifications such as 100mg*60 tablets are priced at more than 20,000 yuan, and in some areas it may even be as high as 60,000 yuan per box, which is a heavy burden for ordinary families.

In general, platinib, as an innovative drug for precision treatment of RETfusion cancer, has been gradually promoted globally since it was first launched in 2020. It isRETPositive cancer patients bring new treatment hope and also reflect the increasing importance of targeted therapy in cancer treatment strategies. With the further adjustment of medical insurance policies in the future and the emergence of generic drugs, it is expected to reduce the financial burden of patients and improve drug accessibility while ensuring the efficacy.

Reference materials:https://gavreto.com/